
    
      This study consists of two parts. Part A is a dose escalation study to determine the maximum
      tolerated dose (MTD) and recommended phase II dose (RP2D) of MRG004A. Part B is a disease
      specific multi-cohort dose expansion study to further assess the efficacy and safety of
      MRG004A at confirmed RP2D.
    
  